SCHEMBL900395

SCHEMBL900395

Cc1cccc(/C(=N\C2CCN(C)CC2)c2nc3ccccc3s2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UBE2M P61081 5/20 0.49
DCUN1D1 Q96GG9 5/20 0.49
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.43
RAB9A P51151 4/20 0.43
MAPT P10636 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
NPC1 O15118 2/20 0.43
SCD O00767 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 4/20 0.40
HPGD P15428 2/20 0.40
MAPK1 P28482 1/20 0.40
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL900396 1.00 UBE2M (0.49) UBE2MDCUN1D1LMNASMN1; SMN2RAB9A
SCHEMBL900212 0.83 MAPT (0.45) UBE2MDCUN1D1SMN1; SMN2RAB9AMAPT
SCHEMBL900213 0.83 MAPT (0.45) UBE2MDCUN1D1SMN1; SMN2RAB9AMAPT
SCHEMBL900539 0.78 RAB9A (0.49) LMNASMN1; SMN2RAB9AMAPTMEN1
SCHEMBL900538 0.78 RAB9A (0.49) LMNASMN1; SMN2RAB9AMAPTMEN1
SCHEMBL900711 0.71 SCD (0.62) UBE2MDCUN1D1LMNASMN1; SMN2RAB9A
SCHEMBL18657973 0.66 UBE2M (1.00) UBE2MDCUN1D1LMNAMAPTMEN1
SCHEMBL27200342 0.66 RAB9A (0.46) SMN1; SMN2RAB9AMAPTMEN1KMT2A
SCHEMBL2720681 0.65 CHRM2 (0.49) UBE2MDCUN1D1LMNACYP2D6HPGD
SCHEMBL899905 0.65 UBE2M (0.42) UBE2MDCUN1D1LMNASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2621916-B1 BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS BIOPROJET SOC CIV (FR) 2016-02-10 EP disclosed
US-9029357-B2 Benzazole derivatives as histamine H4 receptor ligands BIOPROJET (FR) 2015-05-12 US disclosed
US-20150004181-A1 Benzazole Derivatives as Histamine H4 Receptor Ligands BIOPROJET SOC CIV (FR) 2015-01-01 US disclosed
US-8802664-B2 Benzazole derivatives as histamine H4 receptor ligands BIOPROJECT (FR) 2014-08-12 US disclosed
US-20130231329-A1 Benzazole Derivatives as Histamine H4 Receptor Ligands BIOPROJET (FR) 2013-09-05 US disclosed
EP-2621916-A1 BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS BIOPROJET (FR) 2013-08-07 EP disclosed
EP-2447263-A1 Benzazole derivatives as histamine H4 receptor ligands BIOPROJET (FR) 2012-05-02 EP disclosed
WO-2012041860-A1 BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS BIOPROJET (FR) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150004181-A1 Benzazole Derivatives as Histamine H4 Receptor Ligands HRH4, HRH3, HRH2 UBE2M 3664/4885DCUN1D1 3863/4885LMNA 4499/4885
US-20130231329-A1 Benzazole Derivatives as Histamine H4 Receptor Ligands HRH4, HRH3, HRH2 UBE2M 4320/4885DCUN1D1 4074/4885LMNA 4416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.